Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Thyroidectomy Still Popular Despite Less Aggressive Treatment Recommendations

April 16, 2019
By Naveed Saleh, MD, MS
Article

A recent study evaluated the impact of recommendations encouraging less aggressive lobectomy for patients with small papillary thyroid cancers.

The number of total thyroidectomies has not gone down despite recommendations encouraging less aggressive lobectomy for patients with small papillary thyroid cancers, according to the results of a recent study published in the journal Surgery.

“Guidelines are saying that doing less is probably better. Why do people not adopt the guidelines? This is everybody’s big question,” said Naifa Lamki Busaidy, MD, director of the Thyroid Nodule Clinic at The University of Texas MD Anderson Cancer Center in Houston, in an exclusive interview with Cancer Network.

In a retrospective cohort study, James et al mined data from the National Cancer Institute Surveillance, Epidemiology, and End Results cancer registries. During the 14-year study period (2000–2014), 44,537 patients received surgical treatment for papillary thyroid cancer (77% female; 81.3% white).

The researcher found that the incidence of papillary thyroid cancer doubled during this time period, from 6.2 to 13.0 cases per 100,000. Furthermore, the proportion of total thyroidectomy among all papillary patients increased from 78.16% in 2000 to 85.67% in 2014, whereas the proportion of thyroid lobectomy decreased from 16.62% to 11.41%. During the study period, a widening gap was noted in terms of the proportion of total thyroidectomy to thyroid lobectomy, after stratifying by tumor size.

About 46% of patients were diagnosed between the ages of 40 and 59 years, and 27.6% were diagnosed between the ages of 20 and 39 years. Nearly one-third of the tumors were < 1 cm in size, and 8.6% were > 4 cm. Furthermore, 64% of cancers were localized, and only 2.5% of cancers were metastatic. In total, 84.3% of patients underwent a total thyroidectomy while 12.4% had a thyroid lobectomy.

Thyroid cancer incidence has increased by 3% annually during the past several decades-most of which are small papillary thyroid cancers. Factors that may be contributing to this trend include increased rates of diagnostic radiography or use of flame-retardant chemicals, although the majority of this increase is likely due to incidental findings.

“Multiple studies have shown that this change in incidence has not been associated with a change in mortality,” wrote James and coauthors. “This finding gains more significance when placed in the context of the significant financial and psychologic burden attributed to thyroid cancer treatment.”

In light of overdiagnosis and overtreatment of nonaggressive papillary thyroid cancers, significant changes in the recommendations for surgical treatment of thyroid cancer have transpired over the past 12 years.

In 2009, the American Thyroid Association (ATA) updated its guidelines to recommend defining thyroid lobectomy as cancers ≤ 1.5 cm. Other guidelines have recommended thyroid lobectomy as a safe option for the treatment of papillary thyroid cancers ≤ 4 cm in size.

In light of changing recommendations, Busaidy wonders why such low rates of lobectomy for the treatment of papillary thyroid cancer are reported in the current study. “I can’t explain why total thyroidectomy rates went up by that much and lobectomies went down. How do you explain that? You always think of biases,” she said.

According to Busaidy, there are several potential reasons why the frequency of lobectomies noted in the study was low.

First, in community settings where many thyroid surgeries are performed, the decision to perform a lobectomy vs total thyroidectomy may rest with a general surgeon, who might have limited knowledge of current guidelines. In other words, specialists such as endocrinologists and oncologists may not be making the call for lobectomy in conjunction with surgeons. “One [explanation] is that nobody’s read a book; they’re operating and not keeping up because they do 20 other surgeries,” she said. “They’ve kept up with some technology, but not necessarily a rare disease that you occasionally operate on.”

Second, there exists room for interpretation in guidelines, and some specialists may be consciously choosing to overtreat based on anecdotal experience. “It’s human nature to be burned by your experiences. Your own experiences will tell you how to treat things, and this is very common with physicians,” Busaidy said.

Third, the decision to overtreat with thyroidectomy may be rooted in concerns about litigation. “I feel that if people undertreat they are more fearful of being sued than [of] overtreatment,” she said.

Finally, patients themselves may be requesting total thyroidectomies with the misguided notion that the cancer will never return if the thyroid is totally resected.

Busaidy reiterated that thyroid cancer treatment guidelines have changed in 2005, 2009, and, most recently, in 2016, to recommend less aggressive treatment. Although she finds the James et al study to be well done, breaking up the follow-up period to better reflect changes in guidelines would be a good idea, she said.

Pooja Manroa, MD, an endocrinologist and assistant professor of medicine at the University of Pittsburgh School of Medicine in Pittsburgh, also spoke with Cancer Network about the implications of the study results.

“This study underscores the need to address the delay in adoption of professional guidelines and demonstrates clearly that two iterations of ATA guidelines did not impact the clinical decision-making for low risk thyroid cancers,” she said. “Other factors that may be playing a role in physician and patient decision-making should be carefully evaluated and addressed.”

Nevertheless, Manroa is optimistic that lobectomy rates will go up. “As the latest set of ATA guidelines on management of thyroid nodules and differentiated thyroid cancers was released in 2016, as well as the results of studies from centers advocating observation vs surgery in low-risk thyroid cancers [from] Kuma Hospital in Japan and Memorial Sloan Kettering Cancer Center are available, I anticipate that the incidence and proportion of lobectomy for thyroid cancers will rise over time,” she said.

Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Related Content
Advertisement

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

Roman Fabbricatore
February 9th 2025
Article

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.


Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

Russ Conroy
October 8th 2024
Article

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Related Content
Advertisement

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

Roman Fabbricatore
February 9th 2025
Article

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.


Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

Russ Conroy
October 8th 2024
Article

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.